GPCR vs. NVO
GPCR (Structure Therapeutics Inc. American Depositary Shares) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — GPCR in Biotechnology, NVO in Drug Manufacturers - General. Over the past 3 years, GPCR returned 15.87%/yr vs -13.64%/yr for NVO. At a 0.18 correlation, their price movements are largely independent.
Performance
GPCR vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GPCR achieves a -34.42% return, which is significantly lower than NVO's -3.54% return.
GPCR
- 1D
- 0.22%
- 1M
- 16.38%
- YTD
- -34.42%
- 6M
- -36.02%
- 1Y
- 106.38%
- 3Y*
- 15.87%
- 5Y*
- —
- 10Y*
- —
NVO
- 1D
- 3.36%
- 1M
- 5.47%
- YTD
- -3.54%
- 6M
- -4.91%
- 1Y
- -28.81%
- 3Y*
- -13.64%
- 5Y*
- 5.10%
- 10Y*
- 8.62%
GPCR vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
GPCR Structure Therapeutics Inc. American Depositary Shares | -34.42% | 156.45% | -33.46% | 63.04% |
NVO Novo Nordisk A/S | -3.54% | -39.22% | -15.93% | 58.35% |
Correlation
The correlation between GPCR and NVO is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Feb 3, 2023 | 0.18 |
Fundamentals
GPCR:
$3.30B
NVO:
$210.96B
GPCR:
-$2.75
NVO:
DKK 27.42
GPCR:
2.28
NVO:
6.80
GPCR:
$0.00
NVO:
DKK 327.80B
GPCR:
$0.00
NVO:
DKK 268.30B
GPCR:
-$191.27M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GPCR vs. NVO — Risk / Return Rank
GPCR
NVO
GPCR vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Structure Therapeutics Inc. American Depositary Shares (GPCR) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GPCR | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.46 | ||
| Sortino ratioReturn per unit of downside risk | +3.65 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 0.93 | +0.42 |
| Calmar ratioReturn relative to maximum drawdown | 1.73 | -0.59 | +2.32 |
| Martin ratioReturn relative to average drawdown | 3.50 | -0.93 | +4.44 |
Loading charts...
Drawdowns
GPCR vs. NVO - Drawdown Comparison
The maximum GPCR drawdown since its inception was -80.96%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for GPCR and NVO.
Loading charts...
Drawdown Indicators
| GPCR | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -80.96% | -74.70% | -6.26% |
Max Drawdown (1Y)Largest decline over 1 year | -61.74% | -49.17% | -12.57% |
Max Drawdown (3Y)Largest decline over 3 years | -80.96% | -74.70% | -6.26% |
Max Drawdown (5Y)Largest decline over 5 years | — | -74.70% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -51.37% | -65.54% | +14.17% |
Average DrawdownAverage peak-to-trough decline | -42.14% | -17.81% | -24.33% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.48% | 30.87% | -0.39% |
Volatility
GPCR vs. NVO - Volatility Comparison
Structure Therapeutics Inc. American Depositary Shares (GPCR) has a higher volatility of 13.41% compared to Novo Nordisk A/S (NVO) at 12.04%. This indicates that GPCR's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GPCR | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.41% | 12.04% | +1.37% |
Volatility (6M)Calculated over the trailing 6-month period | 42.46% | 38.41% | +4.05% |
Volatility (1Y)Calculated over the trailing 1-year period | 119.06% | 52.06% | +67.00% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 98.46% | 38.48% | +59.98% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 98.46% | 32.58% | +65.88% |
Dividends
GPCR vs. NVO - Dividend Comparison
GPCR has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.80%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GPCR Structure Therapeutics Inc. American Depositary Shares | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 3.80% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
GPCR vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Structure Therapeutics Inc. American Depositary Shares and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
GPCR and NVO have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GPCR has higher volatility (13.41%) compared to NVO (12.04%). In terms of maximum drawdown, GPCR dropped -80.96% vs NVO's -74.70%.
GPCR currently has the higher Sharpe Ratio (0.90 vs -0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GPCR and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer